Skip to content
Psychedelic Alpha· Josh·· 17 days agoAI score56

Compass says COMP360 NDA will be filed within two weeks

Compass Says NDA Will Be Filed Within Two Weeks, Declines to Comment on Usona

AI summary

Compass Pathways said in its Q3 2026 results that its NDAA new drug application, the formal request asking the FDA to approve a new medicine for sale in the United States.Open the glossary for COMP360 psilocybin for treatment-resistant depressionDepression that has not improved enough after adequate courses of at least two antidepressant treatments.Open the glossary (TRD) is nearing completion and will be filed in the next two weeks. The release describes the final NDA submission as nearing completion. The company declined to comment on Usona.

Key facts

Compound
Psilocybin
Condition
Depression
Organisation
Compass Pathways
Source
Psychedelic Alpha (psychedelicalpha.com)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: Psychedelic Alpha · psychedelicalpha.com

Connected to

Compound
Psilocybin
Condition
Depression
Organisation
Compass Pathways

Other recent items on these topics